ACAD - NASDAQ
ACADIA Pharmaceuticals Inc.
$21.57
+2.2%ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
At a Glance
Live SnapshotACADIA Pharmaceuticals Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
ACADIA Pharmaceuticals Inc. Income Statement
ACAD • NASDAQ
| ACADIA Pharmaceuticals Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
1.1B | 957.8M | 726.4M | 517.2M | 484.1M | 441.8M | 339.1M | 223.8M | 124.9M | 17.3M | 61K | 120K | 1.1M | 4.9M | 2.1M | 42.1M | 6.4M | 1.6M | 7.6M | 8.1M | |
GROSS PROFIT | ||||||||||||||||||||
(89M) | (81.8M) | (45.7M) | (10.2M) | (19.1M) | (20.6M) | (19.6M) | (18.3M) | (13.1M) | (4.4M) | (76.4M) | (60.6M) | (26.7M) | (18.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
982.5M | 876M | 680.7M | 507.1M | 465M | 421.2M | 319.5M | 205.5M | 111.8M | 12.9M | -76.3M | -60.5M | -25.6M | -13.9M | 2.1M | 42.1M | 6.4M | 1.6M | 7.6M | 8.1M | |
OPERATING INCOME | ||||||||||||||||||||
(877.7M) | (645.2M) | (754.1M) | (730.7M) | (635.4M) | (707.8M) | (566M) | (452.9M) | (404.3M) | (285.7M) | (164.7M) | (93.4M) | (39.4M) | (25.8M) | (24.9M) | (27M) | (51.9M) | (68.6M) | (70.2M) | (57.2M) | |
(548.9M) | (488.4M) | (402.5M) | (369.1M) | (396M) | (388.7M) | (325.6M) | (265.8M) | (255.1M) | (186.5M) | (90.8M) | (32.7M) | (12.7M) | (7M) | (7.6M) | (6.5M) | (10.3M) | (11.8M) | (12.3M) | (11.3M) | |
(328.8M) | (303.2M) | (351.6M) | (361.6M) | (239.4M) | (319.1M) | (240.4M) | (187.2M) | (149.2M) | (99.3M) | (73.9M) | (60.6M) | (26.7M) | (18.8M) | (17.3M) | (20.6M) | (41.6M) | (56.8M) | (57.9M) | (49.4M) | |
104.8M | 230.8M | -73.4M | -223.6M | -170.4M | -286.6M | -246.5M | -247.4M | -292.4M | -272.8M | -164.6M | -93.2M | -38.3M | -20.9M | -22.9M | 15.1M | -45.5M | -67M | -62.7M | -49.1M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (37K) | (86K) | (181K) | (0.0) | (0.0) | |
31.7M | 25.5M | 17.2M | 6.6M | 591K | 6.6M | 11.2M | 5.3M | 4.1M | 2.8M | 499K | 755K | 349K | 37K | 87K | 45K | 323K | 2.7M | 0.0 | 0.0 | |
(0.0) | -146.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.8M | (4M) | (1.3M) | (2.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.6M | |
34.1M | 27.3M | 22.3M | 10.2M | 2.9M | 5.6M | 12.2M | 3.5M | 4.1M | 2.8M | 499K | 755K | 349K | 37K | 87K | 45K | 323K | 2.7M | 6.3M | 4M | |
138.9M | 258.1M | -51M | -213.4M | -167.5M | -281M | -234.4M | -243.9M | -288.3M | -270.1M | -164.1M | -92.5M | -37.9M | -20.8M | -22.8M | 15.1M | -45.1M | -64.2M | -56.4M | -45M | |
NET INCOME | ||||||||||||||||||||
-252.1M | (31.6M) | (10.3M) | (2.5M) | (351K) | (611K) | (876K) | (1.3M) | (1.1M) | (1.3M) | (330K) | -206K | (0.0) | -109K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.9M | |
391M | 226.5M | -61.3M | -216M | -167.9M | -281.6M | -235.3M | -245.2M | -289.4M | -271.4M | -164.4M | -92.5M | -37.9M | -20.8M | -22.8M | 15.1M | -45.1M | -64.2M | -56.4M | -45M |
SEC Filings
ACAD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ACAD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.